297 related articles for article (PubMed ID: 26268996)
21. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
22. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer.
Boddy JL; Fox SB; Han C; Campo L; Turley H; Kanga S; Malone PR; Harris AL
Clin Cancer Res; 2005 Nov; 11(21):7658-63. PubMed ID: 16278385
[TBL] [Abstract][Full Text] [Related]
23. Expression of vascular endothelial growth factors VEGF- C and D, VEGFR-3, and comparison of lymphatic vessels density labeled with D2-40 antibodies as a prognostic factors in vulvar intraepithelial neoplasia (VIN) and invasive vulvar cancer.
Jach R; Dyduch G; Radon-Pokracka M; Przybylska P; Mika M; Dulinska-Litewka J; Zajac K; Huras H; Streb J; Stangel-Wojcikiewicz K; Dziadek O; Galarowicz B
Neuro Endocrinol Lett; 2011; 32(4):530-9. PubMed ID: 21876509
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate.
Ravindranath N; Wion D; Brachet P; Djakiew D
J Androl; 2001; 22(3):432-43. PubMed ID: 11330643
[TBL] [Abstract][Full Text] [Related]
25. The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy.
Peyromaure M; Camparo P; Badoual C; Descazeaud A; Dinh-Xuan AT
BJU Int; 2007 May; 99(5):1150-3. PubMed ID: 17437444
[TBL] [Abstract][Full Text] [Related]
26. Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer.
Fukuda H; Tsuchiya N; Narita S; Kumazawa T; Horikawa Y; Inoue T; Saito M; Yuasa T; Matsuura S; Satoh S; Ogawa O; Habuchi T
Oncol Rep; 2007 Nov; 18(5):1155-63. PubMed ID: 17914566
[TBL] [Abstract][Full Text] [Related]
27. [Correlation of the expressions of VEGF-C and VEGFR-3 to the pathological grade of prostate cancer].
Chen H; Zhao GP; Xiao NX; Xia Q; Lai JS; Zheng DS; Zhao ZH; Xin YH
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jan; 31(1):155-9. PubMed ID: 21269982
[TBL] [Abstract][Full Text] [Related]
28. Increased expressions of vascular endothelial growth factor (VEGF), VEGF-C and VEGF receptor-3 in prostate cancer tissue are associated with tumor progression.
Yang J; Wu HF; Qian LX; Zhang W; Hua LX; Yu ML; Wang Z; Xu ZQ; Sui YG; Wang XR
Asian J Androl; 2006 Mar; 8(2):169-75. PubMed ID: 16491267
[TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of SUMO-specific protease 1 (SENP1) in prostate cancer patients undergoing radical prostatectomy.
Li T; Huang S; Dong M; Gui Y; Wu D
Urol Oncol; 2013 Nov; 31(8):1539-45. PubMed ID: 23089540
[TBL] [Abstract][Full Text] [Related]
30. The association of vascular endothelial growth factor receptor-1 with the risk of cancer progression following radical prostatectomy.
Mao K; Camparo P; Badoual C; Peyromaure M; Delongchamps NB; Vieillefond A; Dinh-Xuan AT
Oncol Rep; 2008 Jan; 19(1):171-5. PubMed ID: 18097592
[TBL] [Abstract][Full Text] [Related]
31. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
[TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients.
Mazzucchelli R; Montironi R; Santinelli A; Lucarini G; Pugnaloni A; Biagini G
Prostate; 2000 Sep; 45(1):72-9. PubMed ID: 10960845
[TBL] [Abstract][Full Text] [Related]
33. Associations of nm23H1, VEGF-C, and VEGF-3 receptor in human prostate cancer.
Yang ZS; Xu YF; Huang FF; Ding GF
Molecules; 2014 May; 19(5):6851-62. PubMed ID: 24858271
[TBL] [Abstract][Full Text] [Related]
34. The significance of VEGF-C/VEGFR-2 interaction in the neovascularization and prognosis of nephroblastoma (Wilms' tumour).
Nowicki M; Ostalska-Nowicka D; Kaczmarek M; Miskowiak B; Witt M
Histopathology; 2007 Feb; 50(3):358-64. PubMed ID: 17257131
[TBL] [Abstract][Full Text] [Related]
35. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
36. Increased nuclear factor erythroid 2-related factor 2 expression predicts worse prognosis of prostate cancer patients treated with radical prostatectomy.
Raatikainen S; Aaltomaa S; Kärjä V; Soini Y
Hum Pathol; 2014 Nov; 45(11):2211-7. PubMed ID: 25175169
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma.
Mylona E; Alexandrou P; Mpakali A; Giannopoulou I; Liapis G; Markaki S; Keramopoulos A; Nakopoulou L
Eur J Surg Oncol; 2007 Apr; 33(3):294-300. PubMed ID: 17129704
[TBL] [Abstract][Full Text] [Related]
38. Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns.
Jeltsch M; Karpanen T; Strandin T; Aho K; Lankinen H; Alitalo K
J Biol Chem; 2006 Apr; 281(17):12187-95. PubMed ID: 16505489
[TBL] [Abstract][Full Text] [Related]
39. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
Benko G; Spajić B; Krušlin B; Tomas D
Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
[TBL] [Abstract][Full Text] [Related]
40. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer.
Gravdal K; Halvorsen OJ; Haukaas SA; Akslen LA
Cancer Res; 2009 Jun; 69(11):4708-15. PubMed ID: 19487287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
